Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, Adler AI, Amos C, Attard G, Varughese M, Gale J, Brown S, Srihari N, Birtle AJ, Brown M, Chan K, Chowdhury S, Cross W, Dearnaley DP, Din O, Dutey-Magni P, Gilbert DC, Gilson C, Gray S, Grist E, Hofmann U, Hudson AM, Jain Y, Jeyasangar G, Jones R, Kayani M, Langley RE, Malik Z, Mason MD, Matheson D, McAlpine C, Macnair A, Millman R, Murphy C, Padden-Modi M, Parikh O, Parker C, Rush H, Russell M, Srinivasan R, Sundar S, Tanguay JS, Turco F, Williams P, Sydes MR, Parmar MKB, Brown LC, Clarke NW, STAMPEDE investigators

Open source

DOI
10.1016/s1470-2045(25)00231-1
Published
2025 Aug
Container
The Lancet. Oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-25-00231-1,
  title = {Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.},
  author = {Gillessen S and Murphy L and James ND and Sachdeva A and El-Taji O and Abdel-Aty H and Adler AI and Amos C and Attard G and Varughese M and Gale J and Brown S and Srihari N and Birtle AJ and Brown M and Chan K and Chowdhury S and Cross W and Dearnaley DP and Din O and Dutey-Magni P and Gilbert DC and Gilson C and Gray S and Grist E and Hofmann U and Hudson AM and Jain Y and Jeyasangar G and Jones R and Kayani M and Langley RE and Malik Z and Mason MD and Matheson D and McAlpine C and Macnair A and Millman R and Murphy C and Padden-Modi M and Parikh O and Parker C and Rush H and Russell M and Srinivasan R and Sundar S and Tanguay JS and Turco F and Williams P and Sydes MR and Parmar MKB and Brown LC and Clarke NW and STAMPEDE investigators},
  year = {2025},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(25)00231-1},
  url = {https://doi.org/10.1016/s1470-2045(25)00231-1}
}

RIS

TY  - JOUR
TI  - Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
AU  - Gillessen S
AU  - Murphy L
AU  - James ND
AU  - Sachdeva A
AU  - El-Taji O
AU  - Abdel-Aty H
AU  - Adler AI
AU  - Amos C
AU  - Attard G
AU  - Varughese M
AU  - Gale J
AU  - Brown S
AU  - Srihari N
AU  - Birtle AJ
AU  - Brown M
AU  - Chan K
AU  - Chowdhury S
AU  - Cross W
AU  - Dearnaley DP
AU  - Din O
AU  - Dutey-Magni P
AU  - Gilbert DC
AU  - Gilson C
AU  - Gray S
AU  - Grist E
AU  - Hofmann U
AU  - Hudson AM
AU  - Jain Y
AU  - Jeyasangar G
AU  - Jones R
AU  - Kayani M
AU  - Langley RE
AU  - Malik Z
AU  - Mason MD
AU  - Matheson D
AU  - McAlpine C
AU  - Macnair A
AU  - Millman R
AU  - Murphy C
AU  - Padden-Modi M
AU  - Parikh O
AU  - Parker C
AU  - Rush H
AU  - Russell M
AU  - Srinivasan R
AU  - Sundar S
AU  - Tanguay JS
AU  - Turco F
AU  - Williams P
AU  - Sydes MR
AU  - Parmar MKB
AU  - Brown LC
AU  - Clarke NW
AU  - STAMPEDE investigators
PY  - 2025
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(25)00231-1
UR  - https://doi.org/10.1016/s1470-2045(25)00231-1
ER  -

APA

S, G., L, M., ND, J., A, S., O, E., H, A., AI, A., C, A., G, A., M, V., J, G., S, B., N, S., AJ, B., M, B., K, C., S, C., W, C., DP, D., O, D., P, D., DC, G., C, G., S, G., E, G., U, H., AM, H., Y, J., G, J., R, J., M, K., RE, L., Z, M., MD, M., D, M., C, M., A, M., R, M., C, M., M, P., O, P., C, P., H, R., M, R., R, S., S, S., JS, T., F, T., P, W., MR, S., MKB, P., LC, B., NW, C., & investigators, S. (2025). Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(25)00231-1

Source records